* Note: Prices are in Million (M) USD.
Description:
Agios Pharmaceuticals, Inc. is a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing transformative therapies targeting diseases related to cellular metabolism. With a strong focus on oncology and rare genetic disorders, Agios utilizes its extensive knowledge of metabolic pathways to create innovative treatments that exemplify precision medicine. The company boasts a promising pipeline and actively engages in strategic collaborations to enhance research and development efforts, demonstrating its commitment to advancing scientific understanding and significantly improving patient outcomes through state-of-the-art therapeutic solutions.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $93 M
Debt : $18 M
EBITDA : $-442 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 14 overlapping fiscal years (max 20).Average Free Cash Flow: $-212 M
Average Revenue: $57 M
Revenue Converted To Free Cash Flow (%): -368.8%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $36 M
Revenue 5 Years Ago (2019-12-31): $118 M
Total Growth over 5 Years: -69.0%
5-Year Revenue CAGR (Historical): -20.9%
Forward 5-Year CAGR (Tapered): -18.8%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $58 M
Share Count 5 Years Ago (2020-12-31): $69 M
Company is buying back its own shares, 3 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-7.01
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-7.01
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 14 valid ROE years (max 20).Average ROE: -28.0%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $41.38
52-Week Low: $23.41
Threshold Price (15% Above 52-Week Low): $26.92
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $2,413 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2016-12-31): $0.49
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 10 points to above Agios Pharm (AGIO) stock.
Fair Value PE 12, Industry Based PE 15, Risk-Free Anchored PE (25% MoS) 18.47. Based on these 3 values, average assigned is 15.16. The fair value of Agios Pharm (AGIO) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
